Abstract
When kidney transplantation became clinically feasible about 10 years ago, with the availability of adequate immunosuppressive drugs, the universal hope of workers in this new field was that the task of combating the rejection response of the kidney recipient against his transplant someday might be reduced, if not eliminated, if the prospective organ donor and recipient were matched for tissue isoantigens that could induce the transplantation immune response. Investigation of the possibility of "tissue typing" quickly began in a number of laboratories throughout the world.From the study of large numbers of persons known to have circulating antibodies against the . . .